美高梅附属同济医院消化内科副主任医师
上海市医学会肝病专科分会肝纤维化学组委员
中国老年医学学会消化分会青年委员
上海市医学会内科专科分会青年委员
上海市医学会消化系病专科分会青年委员
Associate Chief Physician of Department of Gastroenterology, Tongji Hospital, School of Medicine, Tongji University
Member of Liver Fibrosis Group, Liver Disease Branch of Shanghai Medical Association
Youth Member of Digestive Branch of Chinese Geriatrics Society
Youth Member of Internal Medicine Branch of Shanghai Medical Association
Youth Member of Gastroenterology Branch, Shanghai Medical Association
擅长消化系统各类疾病的诊疗，尤其擅长慢性肝病及其终末期阶段的临床管理，在改善肝病患者生活质量和疾病预后方面形成自己独到的见解。入选上海市青年拔尖人才（2020），上海市卫健委“新优青“（2017），上海市卫健委 “医苑新星”（2014），上海市同济医院“杰出青年”（2021）。 长期从事慢性肝病与肝纤维化的基础和临床研究，目前在肝病领域主持课题共10项（经费总额260万），其中包括国家自然科学基金2项，省部级课题4项，以第一/通讯作者发表SCI论著12篇，累计IF>60分，其中JCR1区文章8 篇。以第一发明人身份获批专利4 项（含发明1 项）。形成的创新成果主要包 括三个方面：1）HMGB1是肝内免疫炎症反应及纤维化进展的重要调控点；2）调控HMGB1上游信号可延缓肝硬化门脉 高压的进展；3）免疫细胞对HSCs激活的调控是抑制肝纤维化进展的新兴途径。研究数据不仅为基于免疫炎症调控肝纤维化奠定了重要的理论基础，还将从诊断和治疗双重角度更新肝硬化门脉高压症临床诊治指南。
She is good at the diagnosis and treatment of various diseases of digestive system, especially clinical management of chronic liver disease. She has formed her own unique opinions in improving the life quality and prognosis of patients with advanced chronic liver disease. She was selected as one of the Top Young Talents in Shanghai (2020), the "New Outstanding Youth" of Shanghai Health Commission (2017), the "New Star" of Shanghai Health Commission (2014), and the "Outstanding Youth" of Shanghai Tongji Hospital (2021). She has been engaged in both clinical and basic research of chronic liver disease and liver fibrosis for years. In the field of liver disease, she has presided over a total of 10 projects, including 2 funded by the National Natural Science Foundation of China and 4 funded by the provincial institutions. She has published 12 SCI papers as the first/corresponding author, with a cumulative impact factor higher than 60 points. She has held 4 patents (including 1 invention) as the first inventor. The innovation achievements mainly include the following three aspects: 1) HMGB1 is an important regulatory point of hepatic inflammatory responses and fibrosis progression; 2) Regulating the upstream signal of HMGB1 can delay portal hypertension progression in cirrhosis; 3) The regulation of HSCs activation by immune cells is an emerging way to inhibit liver fibrosis progression. These findings not only lay an important theoretical foundation for the regulation of hepatic fibrosis based on inflammation, but also will update the clinical diagnosis and treatment guidelines for cirrhotic portal hypertension from the perspective of both diagnosis and treatment.
